MacroGenics, Inc. (NASDAQ:MGNX) – Equities researchers at Wedbush cut their Q3 2017 earnings per share estimates for shares of MacroGenics in a research note issued to investors on Thursday. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings of ($0.86) per share for the quarter, down from their previous estimate of ($0.85). Wedbush also issued estimates for MacroGenics’ FY2017 earnings at ($3.96) EPS, Q1 2018 earnings at ($0.97) EPS, Q2 2018 earnings at ($0.88) EPS, Q3 2018 earnings at ($0.91) EPS, Q4 2018 earnings at ($0.93) EPS, FY2018 earnings at ($3.68) EPS, FY2019 earnings at ($4.27) EPS, FY2020 earnings at ($3.24) EPS and FY2021 earnings at $3.28 EPS.

A number of other brokerages also recently commented on MGNX. Cowen and Company reissued a “buy” rating on shares of MacroGenics in a research note on Friday. Zacks Investment Research raised shares of MacroGenics from a “sell” rating to a “hold” rating and set a $19.00 price objective for the company in a research note on Tuesday, July 18th. BidaskClub downgraded shares of MacroGenics from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. ValuEngine downgraded shares of MacroGenics from a “sell” rating to a “strong sell” rating in a research note on Thursday. Finally, Morgan Stanley reduced their price objective on shares of MacroGenics from $24.00 to $22.00 and set an “equal weight” rating for the company in a research note on Monday, May 8th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $32.40.

TRADEMARK VIOLATION NOTICE: “Wedbush Analysts Lower Earnings Estimates for MacroGenics, Inc. (MGNX)” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/08/07/wedbush-analysts-lower-earnings-estimates-for-macrogenics-inc-mgnx.html.

Shares of MacroGenics (NASDAQ:MGNX) opened at 17.28 on Monday. The stock’s market cap is $635.87 million. MacroGenics has a 1-year low of $15.70 and a 1-year high of $33.30. The company has a 50 day moving average price of $17.76 and a 200 day moving average price of $18.87.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($1.05) by $0.09. The company had revenue of $1.70 million during the quarter, compared to analysts’ expectations of $15.82 million. MacroGenics had a negative return on equity of 56.81% and a negative net margin of 1,216.51%. The business’s quarterly revenue was down 97.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.12 EPS.

A number of institutional investors have recently added to or reduced their stakes in MGNX. OppenheimerFunds Inc. raised its position in MacroGenics by 9.4% in the first quarter. OppenheimerFunds Inc. now owns 3,323,025 shares of the biopharmaceutical company’s stock valued at $61,808,000 after buying an additional 286,018 shares in the last quarter. BB Biotech AG raised its position in MacroGenics by 17.7% in the first quarter. BB Biotech AG now owns 2,260,000 shares of the biopharmaceutical company’s stock valued at $42,036,000 after buying an additional 340,000 shares in the last quarter. Vanguard Group Inc. raised its position in MacroGenics by 3.4% in the first quarter. Vanguard Group Inc. now owns 1,352,864 shares of the biopharmaceutical company’s stock valued at $25,163,000 after buying an additional 44,680 shares in the last quarter. State Street Corp raised its position in MacroGenics by 20.0% in the first quarter. State Street Corp now owns 1,007,211 shares of the biopharmaceutical company’s stock valued at $18,732,000 after buying an additional 167,720 shares in the last quarter. Finally, Hood River Capital Management LLC raised its position in MacroGenics by 17.2% in the first quarter. Hood River Capital Management LLC now owns 563,143 shares of the biopharmaceutical company’s stock valued at $10,474,000 after buying an additional 82,691 shares in the last quarter. 82.96% of the stock is currently owned by institutional investors and hedge funds.

In other MacroGenics news, SVP Jon Marc Wigginton sold 5,000 shares of MacroGenics stock in a transaction on Monday, June 5th. The shares were sold at an average price of $20.00, for a total value of $100,000.00. Following the transaction, the senior vice president now directly owns 35,000 shares of the company’s stock, valued at $700,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 8.30% of the stock is currently owned by insiders.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Earnings History and Estimates for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.